Message From CSO & R&D President
 
Disease Areas of Focus
 
Overview
Cancer
Atherosclerosis/ Thrombosis
Diabetes
Obesity
Psychiatric Disorders
Alzheimer's Disease
Hepatitis
HIV/AIDS
Rheumatoid Arthritis
Solid Organ Transplant Rejection
 
Recent Accomplishments
 
Pipeline
 
Biologics
 
R&D Facts
 
Clinical Trials Disclosure

 

  » BMS.com Home » Pharmaceutical Research & Development » Disease Areas of Focus » Diabetes
SEARCH INDEX
 

Pharmaceutical Research & Development


Disease Areas of Focus

Diabetes

There is clear evidence of a global epidemic of diabetes. In 1985 an estimated 30 million people worldwide had diabetes, and in 2000 the figure had risen to over 150 million. This figure is expected to rise to almost 350 million by 2025.1 In the United States today, a total of 20.8 million people—about 7.0 percent of the population—have diabetes.2 The disease can lead to serious complications, and the risk for death among people with diabetes is about twice that of people without diabetes of similar age.2

Essential to managing diabetes properly is good blood glucose control, but many patients fail to achieve or maintain it. Despite the availability of many diabetes therapies, there is substantial unmet need for well-tolerated new treatments that provide sustained blood glucose control. A long-time innovator in the development of diabetes therapies, Bristol-Myers Squibb is sustaining its pioneering role with compounds in development to address the unmet needs of diabetics.

Back to Disease Areas

 

1. “Diabetes Prevalence,” International Diabetes Federation, 2006

2. “National Diabetes Fact Sheet, 2005,” Centers for Disease Control and Prevention




[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.